Table 2

Clinical outcomes in patients evaluated at follow-up (30 days)

CharacteristicStandard of careSitagliptinP value
Mortality, n (%)63 (37)31 (18)0.0001
Clinical score reduction, n (%)
 ≥2 points50 (34)72 (52)0.0005
 <2 points67 (46)36 (26)0.0005
Overall improvement of clinical score, n (%)55 (38)83 (60)0.0001
Hospital discharge at day 30, n891200.0008
EIR (IU/day)31 ± 2.830 ± 3.80.83
Glycemia (mg/dL)170 ± 9139 ± 40.002***
Serum creatinine (mg/dL)1.3 ± 0.11.0 ± 0.070.008*
Lymphocyte count (× 10−9/L)1.1 ± 0.071.6 ± 0.20.03^
CRP (mg/L)7.1 ± 0.93.7 ± 0.50.001***^^^
D-dimer (μg/mL)3,507 ± 1,0822,693 ± 5610.50*
Interleukin-6 (ng/L)81 ± 1172 ± 100.55
LDH (units/L)302 ± 21370 ± 180.01^
Ferritin (μg/mL)440 ± 43411 ± 490.66*^
AST (units/L)42 ± 4.628 ± 1.60.005***
ALT (units/L)48 ± 5.543 ± 3.40.41
Procalcitonin (ng/mL)8.9 ± 2.91.4 ± 0.50.01*
Oxygen saturation (%)92 ± 1.096 ± 0.70.004***
  • Data are mean ± SEM unless otherwise indicated.

  • EIR, exogenous insulin requirement; LDH, lactate dehydrogenase; IU, international units.

  • Baseline vs. follow-up sitagliptin: *P < 0.05; ***P < 0.001.

  • Baseline vs. follow-up standard of care: ^P < 0.05; ^^^P < 0.001.